Hims Falls 32% on FTC Privacy Suit-Is Fear Overdone Into Earnings?

The FTC lawsuit made Hims an earnings-test story

The FTC lawsuit did more than spook investors; it arrived after a powerful rebound and now forces the market to judge whether the business can outgrow the headline. Shares are still down about 32% versus their recent high, even though they have also gained more than 121% since its year-to-date low. That clash helps explain the volatility: bulls see a solid business hit by a negative headline, while bears see a momentum-driven valuation colliding with regulation.

Why the allegations hit hard

The timing matters because the suit targets the parts of the model that depend on consumer trust. The FTC alleges Hims shared consumers' sensitive health information with Meta, Snap, and other third parties, while also making subscriptions difficult to cancel and misleading consumers about billing and cancellation practices. For a direct-to-consumer telehealth company, those are not peripheral legal issues; they go to customer acquisition, retention, and brand credibility.

What earnings need to show

That is why the August 10 print matters more than any short-term rebound. Some of the post-lawsuit bounce looked less like a full clearance and more like investors refusing to accept that the story had changed. Now the question is whether results can show the business remains resilient despite the controversy. If they can, fear may unwind. If not, the selloff may still be working through the valuation.